title: In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
abstract: FR264205 is a novel parenteral 3'-aminopyrazolium cephalosporin. This study evaluated the in vitro and in vivo activities of FR264205 against Pseudomonas aeruginosa. The MIC of FR264205 at which 90% of 193 clinical isolates of P. aeruginosa were inhibited was 1 microg/ml, 8- to 16-fold lower than those of ceftazidime (CAZ), imipenem (IPM), and ciprofloxacin (CIP). FR264205 also exhibited this level of activity against CAZ-, IPM-, and CIP-resistant P. aeruginosa. The reduction in the susceptibility of FR264205 by AmpC beta-lactamase was lower than that of CAZ, indicating a relatively high stability of FR264205 against AmpC beta-lactamase, the main resistance mechanism for cephalosporins. Neither expression of efflux pumps nor deficiency of OprD decreased the activity of FR264205. No spontaneous resistance mutants were selected in the presence of FR264205, and the reduction in susceptibility to FR264205 was lower than that to CAZ, IPM, and CIP after serial passage, suggesting that FR264205 has a low propensity for selecting resistance. In murine pulmonary, urinary tract, and burn wound models of infection caused by P. aeruginosa, the efficacy of FR264205 was superior or comparable to those of CAZ and IPM. These results indicate that FR264205 should have good potential as an antibacterial agent for P. aeruginosa.
authors.affiliation: Infectious Diseases, Pharmacology Research Labs, Drug Discovery Research, Astellas Pharma, Inc., 1-6, Kashima 2-Chome, Yodogawa-ku, Osaka 532-8514, Japan. shinobu.takeda@jp.astellas.com
authors.forename: Shinobu
authors.initials: S
authors.lastname: Takeda
authors.forename: Toru
authors.initials: T
authors.lastname: Nakai
authors.forename: Yoshimi
authors.initials: Y
authors.lastname: Wakai
authors.forename: Fumiaki
authors.initials: F
authors.lastname: Ikeda
authors.forename: Kazuo
authors.initials: K
authors.lastname: Hatano
mesh_terms: D000818:Animals; D002056:Burns / Q000150:complications; D002511:Cephalosporins / Q000494:pharmacology* / Q000627:therapeutic use*; D024901:Drug Resistance, Multiple, Bacterial; D008171:Lung Diseases / Q000188:drug therapy / Q000382:microbiology; D051379:Mice; D008813:Mice, Inbred ICR; D008826:Microbial Sensitivity Tests; D009154:Mutation / Q000502:physiology; D011552:Pseudomonas Infections / Q000188:drug therapy* / Q000382:microbiology; D011550:Pseudomonas aeruginosa / Q000187:drug effects* / Q000235:genetics; D014552:Urinary Tract Infections / Q000188:drug therapy / Q000382:microbiology; D014946:Wound Infection / Q000188:drug therapy / Q000382:microbiology; D001618:beta-Lactamases / Q000096:biosynthesis / Q000235:genetics
chemical_list: D002511:Cephalosporins; C519491:ceftolozane; D001618:beta-Lactamases